Merck to Present New Data for VICTRELIS® (boceprevir) and MK-5172 at The American Association for the Study of Liver …

Merck , known as MSD outside of the United States and Canada, announced today that new data from Phase III studies of VICTRELIS® 200 mg Capsules, the company’s oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases .